REV1

DNA repair protein REV1

4,433 patent compounds predicted against REV1, 2,808 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL673606	0.33	3/20
Hydrochloric Acid (SCHEMBL1373922)	0.63	2/20
SCHEMBL3396020	0.59	2/20
SCHEMBL1734029	0.59	2/20
Hydrochloric Acid (SCHEMBL1736301)	0.59	2/20
SCHEMBL1109178	0.56	2/20
SCHEMBL1109382	0.55	2/20
SCHEMBL1373823	0.55	2/20
SCHEMBL1373826	0.55	2/20
SCHEMBL1109346	0.54	2/20
SCHEMBL3161698	0.53	2/20
SCHEMBL403077	0.53	2/20
SCHEMBL79038	0.53	2/20
SCHEMBL1912247	0.53	2/20
SCHEMBL400947	0.52	2/20
SCHEMBL1372466	0.52	2/20
SCHEMBL1372470	0.52	2/20
SCHEMBL2171705	0.52	2/20
SCHEMBL1734028	0.51	2/20
SCHEMBL1373140	0.51	2/20

Germline variants in REV1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full REV1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to REV1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer	PHASE2	COMPLETED
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer	PHASE2	WITHDRAWN
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor	PHASE1/PHASE2	NOT_YET_RECRUITING
S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction	PHASE2	COMPLETED
Satraplatin and Prednisone to Treat Prostate Cancer	PHASE2	COMPLETED
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas	PHASE1	COMPLETED
Nucleoside Therapy in Patients With Telomere Biology Disorders	PHASE1	RECRUITING
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Gemcitabine and Radiation Therapy in Treating Patients With Locally Advanced Upper Gastrointestinal Cancer	PHASE1	COMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype	nan	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC	nan	UNKNOWN
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease	nan	COMPLETED
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
Pesticide Associated Lymphomas: Expression of Treatment Resistance Genes	nan	COMPLETED
Nicotinamide Riboside and Mitochondrial Biogenesis	nan	COMPLETED
Chronic Cough and CANVAS (Cerebellar Ataxia With Neuropathy and Bilateral Vestibular Areflexia Syndrome)	nan	COMPLETED
The Genetic and the Functional Study of DNA Repair System and the Susceptibility to Rheumatoid Arthritis	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a REV1 binder may also engage these)

Protein	Name	Similarity
Q5R4N7	—	1.000	Q5R4N7 →
Q920Q2	—	1.000	Q920Q2 →
Q4KWZ7	—	0.999	Q4KWZ7 →
Q6R3M4	—	0.982	Q6R3M4 →
Q8H2D5	—	0.981	Q8H2D5 →
POLI	DNA polymerase iota	0.981	landscape →
F6RIX4	—	0.976	F6RIX4 →
ERCC5	DNA excision repair protein ERCC-5	0.976	landscape →
Q99MU3	—	0.975	Q99MU3 →
Q7TPQ3	—	0.975	Q7TPQ3 →
Q5XIX3	—	0.975	Q5XIX3 →
I0IUP4	—	0.974	I0IUP4 →
F1N2W9	—	0.974	F1N2W9 →
F1QDI9	—	0.973	F1QDI9 →
O60934	—	0.973	O60934 →
Q7TN31	—	0.972	Q7TN31 →
Q69Z66	—	0.972	Q69Z66 →
P14629	—	0.972	P14629 →
Q9BY84	—	0.972	Q9BY84 →
Q8K4J0	—	0.972	Q8K4J0 →
Q5RCV3	—	0.972	Q5RCV3 →
Q9DG67	—	0.972	Q9DG67 →
P55266	—	0.972	P55266 →
O88974	—	0.971	O88974 →
Q9QXK2	—	0.971	Q9QXK2 →
G9CGD6	—	0.971	G9CGD6 →
Q5R6Z9	—	0.971	Q5R6Z9 →
P35689	—	0.971	P35689 →
Q9BWU0	—	0.970	Q9BWU0 →
Q6NRM6	—	0.970	Q6NRM6 →